CyGene to Launch New Genetic Screening Test
Posted on: Tuesday, 22 July 2008, 09:01 CDT
CyGene Laboratories has announced that it is introducing StrokeScan, a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.
CyGene's StrokeScan analyzes genes that have been associated with the increased risk of stroke and the 'alpha-galactosidase A' gene that is responsible for Fabry disease.
The StrokeScan is said to be based on know-how and intellectual properties that CyGene exclusively licensed from Arndt Rolfs of the University of Rostock, Germany.
Martin Munzer, president and CEO of CyGene, said: "StrokeScan has the ability to save lives. Genetic screening of people in high risk groups is essential in order to identify and then diagnose Fabry disease accurately and at an early stage."
Source: Datamonitor
Related Articles
- Short-Term Hormone Therapy Plus Radiation Ups Survival For Medium-Risk Prostate Cancer Patients
- Mutant Genes In High-risk Childhood Leukemias Identified
- Mutant Genes in High-Risk Childhood Leukemias Identified
- Apthera's NeuVax(TM) Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients
- Aureon Laboratories Introduces Prostate Px(R)+, First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
- New Scoring for MDS Survival Developed
- Cardiocom(TM) Introduces Commander Cellular Telehealth Device
- Prostate Cancer Screening Cuts Death Risk
- Pakistan: Death and Disease Stalk Quake Survivors
- Delay in Radiation Therapy No Risk to Prostate Cancer Patients
 |
 |
User Comments (0)
RSS Feeds